Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 11:10:2087-2095.
doi: 10.2147/OTT.S130285. eCollection 2017.

Can involved-field irradiation replace elective nodal irradiation in chemoradiotherapy for esophageal cancer? A systematic review and meta-analysis

Xiaoyue Wang  1 , Chuanwang Miao  2   3 , Zhen Chen  4 , Wanhu Li  5 , Shuanghu Yuan  3 , Jinming Yu  3 , Xudong Hu  3
Affiliations
Review

Can involved-field irradiation replace elective nodal irradiation in chemoradiotherapy for esophageal cancer? A systematic review and meta-analysis

Xiaoyue Wang et al. Onco Targets Ther. .

Abstract

Chemoradiotherapy is the most common treatment for inoperable esophageal cancer. However, there is no consensus on the delineation of the clinical target volume. Elective nodal irradiation (ENI) is recommended for inoperable esophageal cancer. A few studies have reported a decrease in the incidence of radiation-related toxicity of involved-field irradiation (IFI) for esophageal cancer. A systematic review and pooled analysis were performed to determine whether IFI in definitive chemoradiotherapy was more beneficial than ENI for esophageal cancer. The results showed no significant differences in the overall survival and local control rates between the IFI and ENI arms. Meanwhile, the incidences of esophageal and lung toxicities were significantly decreased in the IFI arm. These results suggest that IFI is a feasible treatment option for locally advanced esophageal cancer, especially to minimize irradiation-related toxicity.

Keywords: chemoradiotherapy; elective nodal irradiation; esophageal cancer; involved-field irradiation; meta-analysis.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Selection criteria of the included studies. Abbreviations: IFRT, involved-field radiotherapy; ENI, elective nodal irradiation; ASTRO, American Society for Radiation Oncology.
Figure 2
Figure 2
Forest plots comparing OS and median OS time outcomes for IFI and ENI. Abbreviations: OS, overall survival; IFI, involved-field irradiation; ENI, elective nodal irradiation; RR, risk ratio; M–H, Mantel–Haenszel; CI, confidence interval; SE, standard error; IV, inverse variance.
Figure 3
Figure 3
Forest plots comparing LCR outcomes for IFI and ENI. Abbreviations: LCR, local control rate; IFI, involved-field irradiation; ENI, elective nodal irradiation; RR, risk ratio; M–H, Mantel–Haenszel; CI, confidence interval.
Figure 4
Figure 4
Forest plots comparing patterns of treatment failure for IFI and ENI. Abbreviations: IFI, involved-field irradiation; ENI, elective nodal irradiation; RR, risk ratio; M–H, Mantel–Haenszel; CI, confidence interval.
Figure 5
Figure 5
Forest plots comparing treatment-related toxicities for IFI and ENI. Abbreviations: IFI, involved-field irradiation; ENI, elective nodal irradiation; RR, risk ratio; M–H, Mantel–Haenszel; CI, confidence interval.
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. - PubMed
    1. Paul S, Altorki N. Outcomes in the management of esophageal cancer. J Surg Oncol. 2014;110(5):599–610. - PubMed
    1. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623–1627. - PubMed
    1. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–1174. - PubMed
    1. Dai T, Shah MA. Chemoradiation in oesophageal cancer. Best Pract Res Clin Gastroenterol. 2015;29(1):193–209. - PubMed

LinkOut - more resources